Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia

A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage therapy for these patients. We studied all adult pa...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Canaani, Jonathan, Nagar, Meital, Heering, Gabriel, Gefen, Chen, Yerushalmi, Ronit, Shem-Tov, Noga, Volchek, Yulia, Merkel, Drorit, Avigdor, Abraham, Shimoni, Avichai, Amariglio, Ninette, Rechavi, Gidi, Nagler, Arnon
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2020
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7289527/
https://ncbi.nlm.nih.gov/pubmed/32577167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27618
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料